2016 American Transplant Congress
Absence of Acute Allograft Rejection in the Early Post Operative Period in a Full Face VCA Recipient with a Positive B-Cell Flow Cytometric Crossmatch Utilizing an Induction Immunosuppression Regimen Including Anti-thymocyte and Anti-CD20 Agents.
Background: The presence of donor-specific antibodies (DSA) to human leukocyte antigen (HLA) convey increased risk of allograft rejection. Patients suffering full-thickness burns to the face…2016 American Transplant Congress
Th17 Development Is Critical for Airway Epithelial Injury After Transplantation.
Department of Immunology, Capital Medical University, Beijing, China.
Background: Development of obliterative bronchiolitis (OB) is the biggest obstacle that limits long-term allograft survival and clinical application of lung transplantation, and the precise mechanisms…2016 American Transplant Congress
Advantages of Computerized Dosing Strategy in Tacrolimus Treatment of Renal Transplant Patients.
Purpose: Tacrolimus (Tac) is widely used in immunosuppression for kidney transplant (KT) patients. Despite this, it is still difficult for expert physicians to achieve and…2016 American Transplant Congress
Factors Predicting Tacrolimus Trough Variability After Lung Transplantation.
The Johns Hopkins Hospital, Baltimore, MD.
Background: Recent data suggests that variability in tacrolimus trough concentrations is associated with acute and chronic rejection. The purpose of this study was to identify…2016 American Transplant Congress
Wound Healing Complications in Kidney Transplant Recipients Receiving Everolimus.
Background: Regimens with de novo everolimus (EVR) are associated with a concentration-dependent incidence of wound healing adverse events (WHAE), but mycophenolate use also is related…2016 American Transplant Congress
Post-Trial Experience with Belatacept: A Large Single Center Experience.
Emory Transplant Center, Atlanta, GA.
Evaluation of belatacept in clinical trials revealed significant improvements in renal function and cardiovascular risk leading to superior survival. Despite these proven benefits higher rates…2016 American Transplant Congress
Conversion to Once-Daily Tacrolimus in Stable Pediatric Liver Transplantation Recipients.
Department of Surgery Organ Transplant Center, Samsung Medical Center, Seoul, Republic of Korea.
Purpose: Pediatric patients are known to have lower compliance than adult patients. Once-daily formulation of tacrolimus may increase compliance in pediatric liver transplant recipients. The…2016 American Transplant Congress
Effects of Immunosuppression and Sun Exposure on Immune Cell Populations in Skin and Blood of Kidney Transplant Recipients.
BackgroundKidney transplant recipients (KTR) receiving sirolimus accrue fewer skin cancers than KTR receiving calcineurin inhibitor (CNI) based immunosuppression, potentially due to effects of sirolimus and…2016 American Transplant Congress
Designing and Synthesizing a Novel Highly Selective Immunoproteasome Inhibitor That Promotes Long Term Heart Allograft Acceptance While Reducing Plasma Cells and Donor Specific Antibodies.
Antibody mediated rejection (AMR) is one of the most important barriers to improving long-term transplant outcomes. Traditional therapies for AMR do not deplete the source…2016 American Transplant Congress
Earlier Repletion of Lymphocytes After Alemtuzumab Induction Is Associated with a Lower Incidence of Infection Following Renal Transplantation.
Imperial College Renal and Transplant Centre, Hammersmith Hospital, London, United Kingdom.
Introduction: Alemtuzumab has been increasingly used as an induction agent in renal transplantation, although the optimal dose is unknown. We have previously reported that alemtuzumab…
- « Previous Page
- 1
- …
- 112
- 113
- 114
- 115
- 116
- …
- 138
- Next Page »